Analysts Set Silence Therapeutics plc (NASDAQ:SLN) Target Price at $40.67

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $40.67.

A number of equities research analysts have issued reports on SLN shares. Morgan Stanley cut their price target on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Chardan Capital reissued a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a research note on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. BMO Capital Markets cut their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group cut their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a report on Tuesday, March 4th.

Hedge Funds Weigh In On Silence Therapeutics

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new position in Silence Therapeutics during the fourth quarter worth $26,000. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after buying an additional 5,233 shares in the last quarter. Barclays PLC boosted its position in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after buying an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Silence Therapeutics in the 4th quarter worth about $69,000. Finally, Virtus ETF Advisers LLC increased its position in shares of Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after acquiring an additional 6,098 shares during the period. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Price Performance

Shares of SLN stock opened at $3.32 on Monday. Silence Therapeutics has a one year low of $3.25 and a one year high of $24.38. The company’s fifty day moving average price is $4.70 and its 200-day moving average price is $10.07. The company has a market capitalization of $99.37 million, a price-to-earnings ratio of -2.11 and a beta of 1.08.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.